---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-269696"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:56:16.415226+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences Q3 net loss $1.9M, cash $12.7M; cash runway through Q3 2026

## Summary
- Net loss for Q3 2025 was $1.9M ($1.77 per share) vs $2.2M ($40.15) in Q3 2024.
- Cash and equivalents $12.7M at Sept 30, 2025, up from $6.5M at Dec 31, 2024.
- Received $9.6M gross proceeds from warrant inducement in September 2025.
- Announced top-line results from PRIME clinical study; plans FDA meeting for Gemini registration path.
- Net cash used in operations $6.3M for 9 months 2025 vs $14.6M in same period 2024.

## SEC filing metadata
- accession: 0001193125-25-269696
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000119312525269696/0001193125-25-269696-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000119312525269696/revb-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-269696
- JSON: https://secwatch.observer/filing/0001193125-25-269696.json
- Plain text: https://secwatch.observer/filing/0001193125-25-269696.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.